Immuneering Corp — Director's Dealing 2025

Jul 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-07-01

Reporting Person: Zeskind Benjamin J. (Director, PRESIDENT AND CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-01	Class A Common Stock	P	2985	$3.3792	Acquired	2305837	Direct
2025-07-02	Class A Common Stock	P	7015	$3.5342	Acquired	2312852	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	894927	Indirect

Footnotes

F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.35 to $3.41. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.45 to $3.64. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

F3: Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.